Y90-Ibritumomab tiuxetan (Y90-IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)-Reference-Cited by-同舟云学术

Y90-Ibritumomab tiuxetan (Y90-IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)

Published:2016-09-28 Issue:4 Volume:35 Page:576-583
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Voegeli Michèle¹,Rondeau Stephanie²,Berardi Vilei Simona²,Lerch Erika³,Wannesson Luciano³,Pabst Thomas⁴,Rentschler Jochen⁵⁶,Bargetzi Mario⁷,Jost Lorenz⁸,Ketterer Nicolas⁹¹⁰,Bischof Delaloye Angelika⁹,Ghielmini Michele³

Affiliation:

1. Medizinische Universitätsklinik; Liestal Switzerland

2. SAKK Coordinating Center; Bern Switzerland

3. Oncology Institute of Southern Switzerland (IOSI); Bellinzona Switzerland

4. Inselspital Bern; Bern Switzerland

5. Universitätsspital Basel; Basel Switzerland

6. Ortenau Klinikum Offenburg; Offenburg Germany

7. Kantonsspital Aarau; Aarau Switzerland

8. Kantonsspital Bruderholz; Bruderholz Switzerland

9. CHUV; Lausanne Switzerland

10. Hirslanden Lausanne SA; Lausanne Switzerland

Publisher